← Nkarta, Inc. (NKTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Nkarta, Inc. (NKTX)
Pharmaceutical Preparations · market cap $193M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Nkarta, Inc. (NKTX) is a clinical-stage pharmaceutical company with a market cap of ~$212M and two Phase 2 assets: a fludarabine/cyclophosphamide conditioning regimen in lupus nephritis and NKX019 in systemic sclerosis. The company carries approximately $27.4M in cash, implying a runway of roughly 2.9 months, making near-term financing an existential concern ahead of meaningful data readouts estimated in Q2 2027.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
- 2027-04-15 (est.)Phase 2 · Fludarabine, Cyclophosphamideimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Fludarabine, Cyclophosphamide | Phase 2 | Lupus Nephritis |
| NKX019 | Phase 2 | Systemic Sclerosis |
Price & technical context
3-month
-20.5%
6-month
+16.9%
12-month
+23.7%
52-wk range
$1.73–$3.67
vs 50-day MA
-0.9%
vs 200-day MA
+1.3%
Realized vol
74.0%
Max drawdown
-79.0%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NKTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.